Editorial, J Pharm Sci Emerg Drugs Vol: 7 Issue: 3
Market Analysis
Assaf
Faculty of Humanities the Hebrew University of Jerusalem, Israel, E-mail: assaf.assis@mail.huji.ac.il
Keywords: drug design technology
The global drug discovery ad drug design technology market is predictable to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% through the forecast period. Growing frequency of chronic diseases, increasing demand for biologics, technological advancements and new product introductions are some of the key factors driving the progress of the market.
The pharmaceutical market in the United Arab Emirates (UAE) witnessed a growth of $3 billion in 2015 and is estimated to become $6 billion in 2020. The substantial growth is driven by increased expenditure on healthcare, mandatory health insurance, and growing medical tourism.
As per the Global Data’s latest research report, the UAE is increasingly gaining popularity as a medical tourism destination due to its low costs of medicines, medical staff with good English fluency and virtually non-existent queues for treatment. The Dubai Health Authority is on a mission to develop the medical tourism sector and strengthen it. It aims to attract about 1.3 million medical tourists annually by 2021. The revenue on medical tourism is expected to grow about 13% annually for the next five years. Another major initiative taken by UAE government is allowing private sector involvement and investment in the development of healthcare with this decision the UAE government's share of total health expenditure fell over from 71.3% in 2015 and estimated to become 60.7% by 2025.
Global market for generic drugs was worth $81 billion in 2008, a figure that is expected to reach $84 billion in 2009. In 2014, the market is expected to amount to $168.7 billion, for a compound annual growth rate (CAGR) of 15% in the 5-year period. And the Sales of generic drugs in Canada rose from $3.0 billion in 2006 to $5.5 billion in 2016 at a rate of growth similar to the other industrialized countries. And also Japan’s generic drugs market is expected to have the highest rate of growth among major markets at 12.2%, increasing from $5.4 billion in 2009 to $9.6 billion in 2014. Generic drugs are also considered to be 74% of the volume of drugs in the Canadian pharmaceutical market in 2016 which is the third highest among the OECD countries after the United States and Germany. Canadians spent $165 per capita on generic drugs in 2016 which is the second highest among the OECD countries after the United States.
The CAGR from 2015 to 2020 is projected at over 22%. The biosimilars market is expected to be around $6.2 billion by 2020 from only $2.3 billion in 2015. By the tip of this decade the biosimilars would certainly occupy twenty seventh of the whole pharmaceutical market.
Moreover, with the worldwide rise in concern for a lot of accessible-improved- value effective aid, biosimilar drugs would be a more apt choice to the payers, end users, manufacturers over the costly reference biologics. Originator biologics are as costly as about $100,000 per year per patient. Biosimilars on the contrary will be offered at a 30-40% cheaper price than that of the reference product.
However, with all the success stories and opportunities there conjointly lies a serious five hundredth failure rate in developing and getting license towards selling of biosimilars.
The biosimilars market is categorized into mainly four zones – North America(USA and Canada); Europe(UK, Germany, Spain, Italy, France and Rest of Europe); Aisa-Pacific( China, India, Japan, South Korea) and rest of the world ( LATAM and MENA).
Key players of the biosimilars market embody Amgen, Hospira, Teva, Sandoz International GmbH, Dr. Reddy’s Laboratory, Biocon, Roche, Celltrion, Catalent, Mylan and Merck.
The biosimilars development is mainly concentrated in the therapeutic domains of oncology, blood disorders, autoimmune disorders, endocrine disorders and infectious diseases.
• Biosimilars pharmacoeconomic modelling
• Return on Investment(ROI) for biosimilars
• CAGR of biologics and biosimilars in Europe
• Universal Market for Nanotechnology products was evaluated $22.9 billion in 2013 and unanticipated grow to about $26 billion in 2014.
This market is look to achieve regarding $64.2 billion by 2019; a compound annual growth rate (CAGR) is 19.8% from 2014 to 2019.
The global marketplace for nanotechnology-enabled printing technology was approximate to be at total $14 billion in 2013. The market is anticipate to grow at a compound annual rate of growth (CAGR) of seventeen.7% over the next five years and to total $31.8 billion by 2018.
Global Pharmaceutical Market 2019 Industry Research Report is a professional and in-depth study on the current state of the Global Pharmaceutical industry. This report studies international Pharmaceutical in international market, in the countries like North America, China, Europe, India and Japan with production, revenue, consumption, import and export in these regions, from 2014 to 2019, and also forecasts upto 2025.
The Global Pharmaceutical market 2019 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Pharmaceutical market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.
Development policies and plans area unit mentioned likewise as producing processes and value structures also are analyzed. This is associate degree accelerated pace compared to five.2% for the years before 2017 but is slower than the other two large healthcare segments, medical equipment and healthcare services. Healthcare as an entire is growing at over seven-membered year on year. Upstream raw materials and instrumentation and downstream demand analysis is additionally disbursed. The Global Pharmaceutical market development trends and selling channels area unit analyzed. Finally, the practicableness of latest investment comes is assessed, and overall research conclusions offered. The worldwide market for pharmaceuticals came to $1.2 trillion out of 2018, up $100 billion from 2017, as indicated by the Global Use of Medicines report from the IQVIA Institute for Human Data Science. Going ahead, the worldwide market will develop by 4-5% CAGR, coming to $1.5 trillion (in light of receipt evaluating). That rate is lower than the 6.3% CAGR of the 2014-2018 period.
For the US explicitly, the 2018 spending was $485 billion, up 5.2% over the earlier year, and the 2023 spending will be $625-655 billion, speaking to a 4-7% CAGR over the five-year time frame. For quite a while now, IQVIA has been mindful so as to recognize "receipt" income (pretty much proportional to list estimating) from "net" income—the income that really gathers to the pharmaceutical company business once discounts and conclusions area unit calculated in. US net income is relied upon to have risen 1.3% during 2018, and at a 0-3% rate throughout the following five years. Asian pharmaceutical advertise is ascending at a awfully faster rate. As way as development, Singapore is turning into a worldwide place for pharmaceutical industry. Pharmaceutical aggregation and generation trade assumes a major job in Singapore's economy. In 2012, in line with United Nations agency data, Singapore burns through 4.7% of its GDP into medicinal services industry. Also, pharmaceutical trade contributes over eighty fifth of absolute medical specialty sciences fabricating yield of Singapore yearly. According to World Health Organization (WHO), Singapore's medicinal services framework holds 6th position around the world. Singapore's pharmaceutical section pulls in varied outside organizations for ventures. Singapore's worldwide companies and neighborhood new businesses are biggest producers and exporters of medicinal hardware over the world. A few therapeutic items are traded from Singapore, for example, syringes, catheters, look into instruments and logical expository gear. Over 70% of world's smaller scale clusters, 10% of worldwide contact focal points and half of worldwide warm cycles and mass spectrometers are produced in Singapore. The global pharmaceutical market is projected to achieve ten.27 billion USD by 2025. The market is expected to see a growth at 13.1% CAGR owing to increasing incidence of Adverse Drug Reaction. The key driver for the expansion of the pharmaceutical market is ADR’s. In 2015, the U.S. FDA received nearly 253,017 serious adverse events and 44,693 deaths associated with adverse drug reactions (ADRs). This shows the potential demand for instigating safety and pharmaceutical company services.
The datum shows the projected growth of the globe pharmaceutical market by the regional cluster between 2018 and 2022. It is expected that the pharmaceutical market will have a compound annual growth rate of 6 to 9 percent in this period. This datum describes the projected international pharmaceutical market growth for the amount 2016-2021, measured by the compound annual growth rate (CAGR) and sorted by regional submarkets. It is expected that North America will grow at a CAGR of 4.3 percent. The global market for natural & plant-derived drugs was valued at $23.2 billion in 2013 and $24.4 billion in 2014. This total market is expected to reach $35.4 billion in 2020, with a Compound Annual Growth Rate (CAGR) of 6.6% from 2015 to 2020. Pharmaceuticals delineated a US$300 bn-a-year market globally as of 2015, the World Health Organization states. The global pharmaceutical market is anticipated to surpass US$400 bn by 2018. Worldwide prescription drug sales forecasted to grow at a robust 6.5% (CAGR) through 2022 to reach $1.06trn.
